[Frontiers in Bioscience S3, 788-796, January 1, 2011]

Integrin-linked kinase 1: role in hormonal cancer progression

Valerie Cortez1, 2, Binoj C Nair1,3, Dimple Chakravarty1, Ratna K Vadlamudi1

1Department of Obstetrics and Gynecology, 2IMGP-Cancer Biology Program, 3Molecular Medicine Program,University of Texas Health Science Center, San Antonio, TX, USA


1. Abstract
2. Introduction
3. Discussion
3.1. ILK signaling and tumorigenesis
3.2. Expression of ILK in hormonal cancers
3.3. Role of ILK1 in cancer cell metastasis
3.4. ILK-ER signaling crosstalk
3.5. ILK-hormonal therapy resistance
3.6. Therapeutic potential of targeting ILK1 for hormonal cancers
4. Future Perspectives
5. Acknowledgements
6. References


Integrin-linked kinase 1 (ILK1) is a serine/threonine kinase that plays important roles in a variety of cellular functions including cell survival, migration and angiogenesis. ILK1 is normally expressed in numerous tissues and activated by growth factors, cytokines and hormones. Dysregulation of ILK1 expression or function is found in several hormonal tumors including breast, ovary and prostate. Emerging evidence suggests that ILK overexpression promotes cellular transformation, cell survival, epithelial mesenchymal transition (EMT), and metastasis of hormonal cancer cells while inhibition of ILK1 reduces tumor growth and progression. The recent development of ILK1 inhibitors has provided novel mechanisms for blocking ILK1 signaling to curb metastasis and therapy resistance of hormonal tumors. This review will focus on recent advances made towards understanding the role of ILK signaling axis in progression of hormonal cancer.